Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer

Inclusion Criteria: \- Age ≥18 years. Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Adequate organ function within 7 days prior to enrollment, including: Absolute neutrophil count ≥1.5 × 10⁹/L Platelet count ≥80 × 10⁹/L Hemoglobin ≥80 g/L Total bilirubin ≤1.5 × upper limit of normal (ULN) AST and ALT ≤2.5 × ULN (≤5 × ULN in case of liver metastases) Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min Serum albumin ≥30 g/L Estimated life expectancy ≥3 months. Willingness to provide blood samples for circulating tumor DNA (ctDNA) analysis. Signed written informed consent prior to any study-related procedures. Cohort-Specific Inclusion Criteria: Neoadjuvant/Conversion Cohort: 8\. Planned to receive neoadjuvant or conversion systemic therapy followed by potential surgery. 9\. Locally advanced (T3-T4a and/or N+, M0) or oligometastatic disease (≤1 metastatic organ and ≤5 lesions) considered potentially resectable after systemic therapy. 10\. No prior systemic therapy for gastric cancer. Adjuvant Cohort: 11\. Completion of curative-intent surgery for gastric cancer. 12. Pathological stage II-III disease without distant metastasis. 13. Planned to receive standard adjuvant chemotherapy (e.g., XELOX or SOX). Advanced Disease Cohort: 14\. Unresectable or metastatic disease not amenable to curative surgery. 15. Planned to receive systemic therapy, including chemotherapy with or without immunotherapy, as first-line or later-line treatment. 16\. At least one measurable lesion according to RECIST v1.1. Exclusion Criteria: \- History of another malignancy within 5 years, except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer. Uncontrolled central nervous system metastases or primary brain tumors. Severe or uncontrolled comorbidities, including but not limited to: Unstable cardiovascular disease (e.g., recent myocardial infarction, unstable angina, congestive heart failure) Severe infection Active disseminated intravascular coagulation Significant bleeding tendency Significant organ dysfunction that, in the investigator's judgment, would compromise patient safety. Symptomatic pleural effusion or ascites requiring intervention. Any condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study.